Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.60 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.60 |
| ▸ | RARB | P10826 | 5/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750003 | 0.91 | RXRA (0.61) | HCRTR1HCRTR2RARBPLA2G4BCSNK2A2 | |
| SCHEMBL23602940 | 0.88 | HSD17B1 (0.55) | HCRTR1HCRTR2RARBPLA2G4BSMN1; SMN2 | |
| SCHEMBL2228731 | 0.88 | HCRTR1 (0.56) | HCRTR1HCRTR2RARBPLA2G4BCSNK2A2 | |
| SCHEMBL29997664 | 0.88 | HSD17B1 (0.55) | HCRTR1HCRTR2RARBPLA2G4BSMN1; SMN2 | |
| SCHEMBL4817656 | 0.88 | PTPN11 (0.55) | RARBPLA2G4BTP53PKMPTPN11 | |
| SCHEMBL7169579 | 0.86 | RARB (0.72) | RARBPLA2G4BTP53PTPN11 | |
| SCHEMBL9394690 | 0.83 | NR4A2 (0.64) | RARBPLA2G4BRXRARXRBSMN1; SMN2 | |
| SCHEMBL5024584 | 0.83 | SMN1; SMN2 (0.59) | RARBRXRASMN1; SMN2ADH5 | |
| SCHEMBL11507830 | 0.82 | RARB (0.63) | RARBRXRARXRBSMN1; SMN2TP53 | |
| SCHEMBL11584623 | 0.82 | HCRTR1 (0.56) | HCRTR1HCRTR2RARBPLA2G4BCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | HCRTR1 1546/4885HCRTR2 567/4885RARB 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.